The COSMOS Trial. A Pilot Study A Pilot Study

Sponsor
The Cleveland Clinic (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05280574
Collaborator
(none)
100
1
52
1.9

Study Details

Study Description

Brief Summary

The investigators plan a pilot study to evaluate patient tolerance of the GE Portrait Mobile Monitoring Solution, along with appropriate alert thresholds, and clinical utility. Data obtained in the proposed pilot cohort will guide design of a future robust randomized trial comparing clinical interventions and serious complications with blinded versus unblinded continuous ward monitoring.

Condition or Disease Intervention/Treatment Phase
  • Device: GE Portrait Monitor
  • Device: GE Portrait Monitoring with intervened by clinician
  • Device: GE Portrait Monitoring randomized to blinded or unblinded

Detailed Description

The investigators plan a pilot study to evaluate patient tolerance of the GE Portrait Mobile Monitoring Solution, along with appropriate alert thresholds, and clinical utility. The system is a novel battery-powered untethered monitor for continuous monitoring of oxygen saturation, respiratory rate, and pulse rate that is designed for use by patients on surgical wards. The initial phase will evaluate patient tolerance, with clinicians and patients blinded to monitor data. Results will be used to evaluate the frequency of respiratory events and pulse rate abnormalities. These data will be used to design clinical alert settings, based on various durations at various thresholds (e.g., saturation <85% for >1 minute). Our main goal will be to identify clinically meaningful vital sign abnormalities with a minimum of false alerts. Secondarily, the investigators will evaluate the frequency and duration of abnormalities, and the fraction that are detected clinically.

In the second phase of the pilot, clinicians will be unblinded to the GE Portrait monitors, and alerts provided based on the durations and threshold identified in the initial part of the pilot. The primary outcomes will be clinician tolerance and the extent to which clinicians believe that vital sign trending and alerts provided useful information rather than distraction. Specifically, the investigators will assess the fraction of alerts that clinicians deemed meaningful, and the fraction that resulted in clinical interventions. In the third phase of the pilot, the durations and thresholds for saturation, respiratory rate, and pulse rate that trigger alerts will be adjusted based on results from the second phase.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Continuous Ward Monitoring With the GE Portrait Mobile Monitoring Solution: the COSMOS Trial A Pilot Study
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Monitoring without any interventions

All patients will only be monitored with the GE Portrait Monitor with out any interventions.

Device: GE Portrait Monitor
All patients will be monitored

Device: GE Portrait Monitoring randomized to blinded or unblinded
Without intervention

Patients will be randomized to blinded or unblinded GE Portrait monitoring.

All patients will be monitored with the GE Portrait Monitor. Patients who are randomized to the unblinded GE Portrait monitoring might be intervened if the clinicians believe that the alarm is clinically meaningful. Blinded GE Portrait Monitoring will not receive clinicians believe clinically

Device: GE Portrait Monitor
All patients will be monitored

Device: GE Portrait Monitoring with intervened by clinician
Monitoring might be intervened if clinician believe that the alarm is clinically meaningful

Outcome Measures

Primary Outcome Measures

  1. Total duration of time patients experienced vital sign abnormalities in unblinded vs blinded GE Portrait monitoring [Up to 96 hours after surgery]

    The investigators will determine whether patients with unblinded continuous ward monitoring with the GE Portrait Mobile Monitoring Solution experience less time with vital sign abnormalities as defined in the initial phase of the study. Specifically, the investigators will test the primary hypothesis that the cumulative duration of vital sign abnormalities (using criteria determined in Phase 1) is shorter with unblinded than blinded GE Portrait monitoring in patients recovering from major noncardiac surgery.

  2. Vital sign abnormality frequency in unblinded vs blinded GE Portrait monitoring [Up to 96 hours after surgery]

    The investigators will determine whether unblinded continuous ward monitoring with the GE Portrait Mobile Monitoring Solution reduces vital sign abnormalities. Specifically, the investigators will test the primary hypothesis that the cumulative duration of vital sign abnormalities (using criteria refined in Phase 2) is shorter with unblinded than blinded GE Portrait monitoring in patients recovering from major noncardiac surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Are admitted to one of the wards equipped with the GE Portrait Mobile Solution.

  • Are designated American Society of Anesthesiologists physical status 1-4.

  • Had major noncardiac surgery lasting at least 1.5 hours.

  • Are expected to remain hospitalized at least two postoperative nights.

  • Had general anesthesia with or without neuraxial anesthesia.

Exclusion Criteria:
  • Have language, vision, or hearing impairments that may compromise continuous monitoring.

  • Are designated Do Not Resuscitate, hospice, or receiving end of life care

  • Have previously participated in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Cleveland Ohio United States 44195

Sponsors and Collaborators

  • The Cleveland Clinic

Investigators

  • Principal Investigator: Daniel Sessler, MD, The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT05280574
Other Study ID Numbers:
  • 21-970
First Posted:
Mar 15, 2022
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Aug 2, 2022